{"transactions":[{"id":1570877,"issuer":{"id":8699,"kind":"organization","name":"ProPhase Labs, Inc."},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-03-20T01:52:58.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a three year period, with 25% vesting on the date of grant and 25% vesting on each anniversary thereafter, subject to the Reporting Person's continued service through each vesting date"}],"balance_after":500000,"derivative":{"exercise_price":6,"expiration_date":"2031-01-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001493152-24-010575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/868278/000149315224010575/ownership.xml","form_type":"4"}},{"id":2856675,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Stock Option","published_at":"2021-02-17T16:08:50.000Z","date":"2021-02-15","kind":"grant","acquired":true,"shares":100000,"price":0.001,"value":100.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of the first three anniversaries of the date of grant."}],"balance_after":100000,"derivative":{"exercise_price":2.56,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001437749-21-003101","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774921003101/rdgdoc.xml","form_type":"4"}},{"id":3055219,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Stock Option","published_at":"2020-08-18T21:13:35.000Z","date":"2020-08-14","kind":"grant","acquired":true,"shares":100000,"price":0.001,"value":100.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of July 1, 2021, July 1, 2022 and July 1, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest as to one-third on each of July 1, 2021, July 1, 2022 and July 1, 2023."}],"balance_after":100000,"derivative":{"exercise_price":4.7,"expiration_date":"2030-08-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001437749-20-018294","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920018294/rdgdoc.xml","form_type":"4"}},{"id":3055218,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2020-08-18T21:13:35.000Z","date":"2020-08-14","kind":"grant","acquired":true,"shares":50000,"price":0.001,"value":50.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted shares granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan which vest as to one-third on each of July 1, 2021, July 1, 2022 and July 1, 2023."}],"balance_after":107997,"source":{"system":"sec-edgar","filing":"0001437749-20-018294","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920018294/rdgdoc.xml","form_type":"4"}},{"id":3122716,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2020-06-04T16:18:02.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":33997,"price":2.62,"value":89072.14,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock granted under the Amended and Restated 2014 Stock Incentive Plan in lieu of cash bonus."}],"balance_after":57997,"source":{"system":"sec-edgar","filing":"0001437749-20-012480","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920012480/rdgdoc.xml","form_type":"4"}},{"id":3261013,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2020-02-20T16:39:03.000Z","date":"2020-02-20","kind":"purchase","acquired":true,"shares":5000,"price":1.08,"value":5400.0,"ownership":{"direct":true},"balance_after":17950,"source":{"system":"sec-edgar","filing":"0001437749-20-003172","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920003172/rdgdoc.xml","form_type":"4"}},{"id":3285547,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Stock Option","published_at":"2020-02-07T16:15:07.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":100000,"price":0.001,"value":100.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options will vest one-third on each of the first three anniversaries of the date of grant."}],"balance_after":203250,"derivative":{"exercise_price":1.06,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001437749-20-002040","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774920002040/rdgdoc.xml","form_type":"4"}},{"id":3497998,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2019-06-07T16:05:23.000Z","date":"2019-06-05","kind":"purchase","acquired":true,"shares":1000,"price":1.2583,"value":1258.3,"ownership":{"direct":true},"balance_after":12950,"source":{"system":"sec-edgar","filing":"0001437749-19-011608","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919011608/rdgdoc.xml","form_type":"4"}},{"id":3522552,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2019-05-17T16:05:47.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":1000,"price":1.4629,"value":1462.9,"ownership":{"direct":true},"balance_after":11950,"source":{"system":"sec-edgar","filing":"0001437749-19-010383","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919010383/rdgdoc.xml","form_type":"4"}},{"id":3522551,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2019-05-17T16:05:47.000Z","date":"2019-05-16","kind":"purchase","acquired":true,"shares":1500,"price":1.4536,"value":2180.4,"ownership":{"direct":true},"balance_after":10950,"source":{"system":"sec-edgar","filing":"0001437749-19-010383","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919010383/rdgdoc.xml","form_type":"4"}},{"id":3526923,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2019-05-15T16:04:11.000Z","date":"2019-05-15","kind":"purchase","acquired":true,"shares":1000,"price":1.4477,"value":1447.7,"ownership":{"direct":true},"balance_after":9450,"source":{"system":"sec-edgar","filing":"0001437749-19-010054","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919010054/rdgdoc.xml","form_type":"4"}},{"id":3526922,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2019-05-15T16:04:11.000Z","date":"2019-05-14","kind":"purchase","acquired":true,"shares":2000,"price":1.8396,"value":3679.2,"ownership":{"direct":true},"balance_after":8450,"source":{"system":"sec-edgar","filing":"0001437749-19-010054","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919010054/rdgdoc.xml","form_type":"4"}},{"id":3526921,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2019-05-15T16:04:11.000Z","date":"2019-05-13","kind":"purchase","acquired":true,"shares":2400,"price":1.9144,"value":4594.56,"ownership":{"direct":true},"balance_after":6450,"source":{"system":"sec-edgar","filing":"0001437749-19-010054","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919010054/rdgdoc.xml","form_type":"4"}},{"id":3666810,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":true,"officer":true,"officer_title":"CEO, COO & CFO"}}],"security":"Stock Option","published_at":"2019-02-11T18:22:56.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"333,334 options with a strike price of $0.15 will be exercisable on or after 2/7/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.50 per share; 333,333 options with a strike price of $0.30 will be exercisable on or after 12/31/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.70 per share; and 333,333 options with a strike price of $0.50 will be exercisable on or after 12/31/2020, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"333,334 options with a strike price of $0.15 will be exercisable on or after 2/7/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.50 per share; 333,333 options with a strike price of $0.30 will be exercisable on or after 12/31/2019, so long as the closing market price of the underlying common stock equals or exceeds $0.70 per share; and 333,333 options with a strike price of $0.50 will be exercisable on or after 12/31/2020, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share."}],"balance_after":2065000,"derivative":{"expiration_date":"2029-02-07","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001437749-19-002255","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000143774919002255/rdgdoc.xml","form_type":"4"}},{"id":4300531,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"officer_title":"COO and CFO"}}],"security":"Common Stock, $.001 par value","published_at":"2017-05-31T17:28:57.000Z","date":"2017-05-30","kind":"purchase","acquired":true,"shares":7600,"price":0.4364,"value":3316.64,"ownership":{"direct":true},"balance_after":50159,"source":{"system":"sec-edgar","filing":"0001654954-17-005235","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000165495417005235/section16.xml","form_type":"4"}},{"id":4309205,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"officer_title":"COO and CFO"}}],"security":"Common Stock, $.001 par value","published_at":"2017-05-23T17:40:09.000Z","date":"2017-05-22","kind":"purchase","acquired":true,"shares":11200,"price":0.4499,"value":5038.88,"ownership":{"direct":true},"balance_after":42559,"source":{"system":"sec-edgar","filing":"0001654954-17-005032","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000165495417005032/section16.xml","form_type":"4"}},{"id":4309204,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"officer_title":"COO and CFO"}}],"security":"Common Stock, $.001 par value","published_at":"2017-05-23T17:40:09.000Z","date":"2017-05-19","kind":"purchase","acquired":true,"shares":14159,"price":0.4511,"value":6387.1249,"ownership":{"direct":true},"balance_after":31359,"source":{"system":"sec-edgar","filing":"0001654954-17-005032","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000165495417005032/section16.xml","form_type":"4"}},{"id":4312649,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"officer_title":"COO and CFO"}}],"security":"Common Stock, $.001 par value","published_at":"2017-05-19T16:10:36.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":3900,"price":0.4496,"value":1753.44,"ownership":{"direct":true},"balance_after":17200,"source":{"system":"sec-edgar","filing":"0001654954-17-004944","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/810509/000165495417004944/section16.xml","form_type":"4"}},{"id":4312648,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"officer_title":"COO and CFO"}}],"security":"Common Stock, $.001 par value","published_at":"2017-05-19T16:10:36.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":13300,"price":0.467,"value":6211.1,"ownership":{"direct":true},"balance_after":13300,"source":{"system":"sec-edgar","filing":"0001654954-17-004944","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000165495417004944/section16.xml","form_type":"4"}},{"id":4332511,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"officer_title":"COO and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-05T13:42:33.000Z","date":"2017-05-04","kind":"grant","acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"333,334 options with a strike price of $0.65 will be exercisable on or after 5/4/2017, so long as the closing market price of the underlying common stock equals or exceeds $0.85 per share; 333,333 options with a strike price of $0.75 will be exercisable on or after 12/31/2017, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share; and 333,333 options with a strike price of $1.00 will be exercisable on or after 12/31/2018, so long as the closing market price of the underlying common stock equals or exceeds $1.25 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"333,334 options with a strike price of $0.65 will be exercisable on or after 5/4/2017, so long as the closing market price of the underlying common stock equals or exceeds $0.85 per share; 333,333 options with a strike price of $0.75 will be exercisable on or after 12/31/2017, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share; and 333,333 options with a strike price of $1.00 will be exercisable on or after 12/31/2018, so long as the closing market price of the underlying common stock equals or exceeds $1.25 per share."}],"balance_after":1065000,"derivative":{"expiration_date":"2027-05-04","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001654954-17-004110","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000165495417004110/section16.xml","form_type":"4"}},{"id":4571379,"issuer":{"id":107761,"kind":"organization","name":"NAVIDEA BIOPHARMACEUTICALS, INC.","symbol":"NAVB"},"owners":[{"id":88312,"kind":"person","name":"Latkin Jed","position":1,"cik":"0001554593","reported_name":"Latkin Jed","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-11-01T10:29:10.000Z","date":"2016-10-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests to the extent of 10,000 shares each month over a period of two months commencing November 20, 2016."}],"balance_after":20000,"derivative":{"exercise_price":1,"expiration_date":"2026-10-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001144204-16-130730","document":"v451739_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/810509/000114420416130730/v451739_4.xml","form_type":"4"}}]}